Protalix BioTherapeutics to Present Phase I PRX-115 Data at ACR Convergence 2024

Protalix BioTherapeutics, Inc., a biopharmaceutical company based in Carmiel, Israel, announced on October 25, 2024, that pivotal data from its phase I clinical trial of PRX-115 will be showcased at the American College of Rheumatology (ACR) Convergence 2024. This significant event is scheduled to occur from November 14 to 19, 2024, at the Walter E. Washington Convention Center in Washington, D.C.

PRX-115 is Protalix's innovative recombinant PEGylated uricase product candidate developed for treating uncontrolled gout. The most recent findings from this clinical trial will be presented in a late-breaking poster session, highlighting the prolonged plasma urate-lowering effects observed after a single intravenous dose of PRX-115 in participants with elevated urate levels. This presentation will be led by Orit Cohen Barak, Ph.D., from Protalix Ltd., on November 18, 2024, between 10:30 AM and 12:30 PM Eastern Standard Time.

Protalix BioTherapeutics has pioneered the development, production, and commercialization of recombinant therapeutic proteins through its unique proprietary plant cell-based expression system known as ProCellEx®. This method represents a breakthrough in producing recombinant proteins on an industrial scale using plant cells grown in suspension culture. Protalix has achieved a milestone by gaining U.S. Food and Drug Administration (FDA) approval for a protein produced via this system.

Protalix's first product developed using ProCellEx, taliglucerase alfa, is used for treating Gaucher disease. The company has entered a global licensing agreement with Pfizer Inc. for the development and commercialization of taliglucerase alfa, excluding Brazil, where Protalix retains exclusive rights. Additionally, Elfabrio®, Protalix's second product, received approval from both the FDA and the European Medicines Agency in May 2023. Protalix has partnered with Chiesi Farmaceutici S.p.A. for the worldwide development and commercialization of Elfabrio.

Protalix's pipeline includes several other promising candidates, such as PRX-115, the recombinant PEGylated uricase for uncontrolled gout treatment, and PRX-119, a plant cell-expressed long-acting DNase I for treating NETs-related diseases. These innovative products target well-established pharmaceutical markets and showcase Protalix's expertise in developing novel therapeutic proteins.

The upcoming presentation at ACR Convergence 2024 is expected to provide valuable insights into the efficacy of PRX-115 and its potential as a new treatment option for patients suffering from uncontrolled gout. This phase I clinical trial data will shed light on the therapeutic benefits of PRX-115 and reinforce Protalix's position as a leader in the biopharmaceutical industry.

Protalix continues to advance its mission of developing groundbreaking treatments for various diseases by leveraging its proprietary technology platform and strategic collaborations with leading pharmaceutical companies. The company's commitment to innovation and excellence in therapeutic protein development is evident through its expanding product portfolio and successful clinical trials.

As Protalix BioTherapeutics prepares for the ACR Convergence 2024 presentation, the biopharmaceutical community eagerly anticipates the detailed findings on PRX-115, which could mark a significant advancement in the treatment of gout and related conditions.